Tumor-infiltrating regulatory T cell dual surface markers

This target consists of two undisclosed cell-surface antigens that are specifically co-expressed on regulatory T cells (Tregs) infiltrating the tumor microenvironment (TME) (NCI Drug Dictionary). By targeting these dual markers simultaneously, therapeutic agents like the bispecific antibody AGEN1223 are designed to selectively deplete immunosuppressive tumor-infiltrating Tregs while sparing essential peripheral Tregs and effector T cells (Agenus Press Release, 2020). This selective depletion is intended to relieve local immunosuppression within the TME and enhance the overall anti-tumor immune response (NCI Drug Dictionary). Additionally, the interaction with these markers may provide co-stimulatory signals to antigen-specific effector T cells, further promoting tumor cell destruction (Agenus Press Release, 2020). The program was notably part of a major immuno-oncology partnership between Agenus and Gilead Sciences, although clinical development of AGEN1223 was discontinued in 2021 (Agenus 10-K, 2024). This strategy represents a next-generation approach to immunotherapy by focusing on the precise modulation of the immune cell infiltrate within tumors to overcome resistance to standard checkpoint inhibitors.

Other names

Undisclosed tumor-infiltrating Treg-specific antigensIntratumoral regulatory T cell dual surface markersAGEN1223 target

Selective depletion of tumor-infiltrating regulatory T cells (Tregs) via bispecific antibody-mediated mechanisms (such as ADCC or ADCP) and potential co-stimulation of effector T cells.